SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is trending amid reports of a potential rug pull, with many users reporting lost funds and the inability to sell. The community is expressing frustration and investigating the coin's legitimacy, while others are warning about the risks associated with unaudited crypto projects on platforms like Phantom Wallet. Speculation is high as users try to understand what happened to their investments.

The Next Big Secret. $NOWK is a stealthy, community-driven meme token on Solana. Be part of the exclusive early adoption stage and unlock the potential of this hidden gem.  NOWK is based on the viral meme No One Will Know which took the internet by storm! NOWK has something for everyone!  Everybody has something No One Will Know.  Your secrets are safe but not your MEMES! NOWK is the meme of memes!

NOWK

NOWK is trending amid community excitement surrounding its presence on Phantom Wallet. Early interest and perceived 'moon vibes' are fueling discussions, with many viewing it as a potential gem within the Solana ecosystem.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other Hong Kong-based stocks that have recently seen significant gains. Community members are pointing to the company's regained NASDAQ compliance and a substantial contract that exceeds its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

CVNA is trending amid discussions about the company's financial health and potential risks associated with subprime auto loans. Community members are debating the impact of rising delinquencies and the stability of Carvana's ABS deals, while some highlight insider selling and analyst ratings. The stock's high valuation and potential for a short squeeze are also being actively discussed.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI Life Sciences is trending due to FDA breakthrough therapy designation for its depression treatment, BPL-003, sparking significant community excitement. Discussions center around the potential for fast-tracked approval and the impact on the mental health crisis, though some express concern over a recent equity raise. Investors are closely watching upcoming Phase 3 trials and analysts are raising price targets, creating a buzz around ATAI's future prospects in the growing psychedelic medicine sector.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on September 3, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave ($VWAV) is trending as traders discuss its AI-powered defense technology, particularly following successful live-fire trials and news of a potential short squeeze. The community is focused on the high borrow fees for short shares and catalysts like upcoming demonstrations and potential contract news. Some are comparing VWAV to $PLTR, citing its focus on the AI and defense sectors.

Houston American Energy Corp. is an independent oil and gas company, which engages in the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. The firm holds interest in the Texas Permian Basin, the onshore Texas and Louisiana Gulf Coast region and in the South American country of Colombia. It operates through the North America and South America geographical segments. The company was founded on April 2, 2001 and is headquartered in Houston, TX.

Houston American Energy Corp

HUSA is trending amid community discussions about company management, share dilution, and potential for a squeeze. Some traders are closely monitoring geopolitical tensions and oil prices, anticipating a positive impact on the stock. Others express frustration with the stock's performance, citing concerns about the company's financials.

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Solana Co. - Ordinary Shares - Class A

Solana Co

HSDT is trending due to a recent announcement of a $500M funding round to launch a Solana-backed treasury, sparking significant volatility and mixed reactions from traders. Community members are debating whether this move will be a game-changer or a dilution trap, while also watching for potential short squeezes and FDA catalyst news. The stock is seeing both bullish and bearish sentiment, with some eyeing price targets, while others cite concerns about dilution and the company's history.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

DCTH is trending as investors analyze recent CHOPIN trial data presented at #esmo2025, specifically regarding survival rates and adverse events associated with combination therapy. Community members are actively weighing the potential for significant upside, acquisition possibilities, and the stock's overall volatility in response to the data. Discussions also include Blackrock's stake in DCTH and its implications.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending due to recent FDA Fast Track designation for its AlloNK therapy, which is intended to treat refractory rheumatoid arthritis, sparking optimism. The community is discussing the potential for significant upside, citing analyst upgrades and price targets, while also debating the possibility of a near-term offering. Traders are closely watching regulatory filings and ATM usage to gauge the company's financial strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYDY nice to see the newly updated clinical objectives in the FAQ section on CYDY site. They are giving us the game plan. My ideas of their goals: 
 
i. Colorectal phase 2 trial: fill the trial as fast as possible to build data for BTD breakthrough therapy designation which is worth billions for a large oncology indication like CRC, the 3rd most common cancer worldwide 
 
ii. Expand oncology indications beyond TNBC - preclinical data is the most cost-effective method to do this and with the newly discovered moa this is the fastest indication to building shareholder value 
 
iii. Long-acting Leronlimab development- CYDY already mentioned almost a year ago that they have several versions of long-acting leronlimab &amp; continue researching &quot;new or modified&quot; versions tells me they&#39;re working at finding the best version humanly possible w the assistance of our AI partner.  
 
This ties into HIV CURE! 
 
Long-acting wasn&#39;t mentioned in the letter &amp; I&#39;m very happy this is a priority! 
 
Partnerships r top priority!

LadyDuckSnot

NATE

J Valro

Timothy OConnor

vivamiga

christopher

JRLL

StockTwits Web

CytoDyn Inc

 nice to see the newly updated clinical objectives in the FAQ section on CYDY site. They are giving us the game plan. My ideas of their goals: 
 
i. Colorectal phase 2 trial: fill the trial as fast as possible to build data for BTD breakthrough therapy designation which is worth billions for a large oncology indication like CRC, the 3rd most common cancer worldwide 
 
ii. Expand oncology indications beyond TNBC - preclinical data is the most cost-effective method to do this and with the newly discovered moa this is the fastest indication to building shareholder value 
 
iii. Long-acting Leronlimab development- CYDY already mentioned almost a year ago that they have several versions of long-acting leronlimab & continue researching "new or modified" versions tells me they're working at finding the best version humanly possible w the assistance of our AI partner.  
 
This ties into HIV CURE! 
 
Long-acting wasn't mentioned in the letter & I'm very happy this is a priority! 
 
Partnerships r top priority!

SpiderPlant40

@SpiderPlant40 you can&#39;t even copy and paste without embellishing... 
i. Continue the pending Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer; 
 
ii. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and 
 
iii. Continue our work researching and developing a new or modified long-acting version of leronlimab. 
 
1. how do you &quot;continue the pending&quot;... it hasn&#39;t started... this is a lie... 
2. studies in mice are not a &quot;clinical objective&quot;... it is a &quot;PRE-clinical objective&quot;.... 
3. if a molecule DOES NOT EXIST like LALL, once again, it is NOT a &quot;clinical objective&quot;... 
 
just another example of CYDY FRAUD...

 you can't even copy and paste without embellishing... 
i. Continue the pending Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer; 
 
ii. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and 
 
iii. Continue our work researching and developing a new or modified long-acting version of leronlimab. 
 
1. how do you "continue the pending"... it hasn't started... this is a lie... 
2. studies in mice are not a "clinical objective"... it is a "PRE-clinical objective".... 
3. if a molecule DOES NOT EXIST like LALL, once again, it is NOT a "clinical objective"... 
 
just another example of CYDY FRAUD...

mazzy star

@mazzystar1 it&#39;s not a copy &amp; paste, these are my thoughts of their goals in each listed priority  
 
I&#39;m beginning to ? your comprehension or maybe your hatred of all things Cytodyn has diminished your ability to read.  
 
Here r the answers to ur dumb ?s: 
 
i. You &quot;continue the pending&quot; by continuing to add additional sites &amp; get the 1st shots into suffering patients arms. The trial is pending &amp; continuing the work will turn pending into active duhhh 
 
ii. Pre-clinical objectives are what leads to smart clinical objectives. You&#39;d rather they skip the groundwork so than you can go back &amp; say they should&#39;ve down pre-clinical work 1st. They&#39;re doing it the right way for future success 
 
iii. The molecules exist &amp; they have to chose which one is best which takes lots of time modifying &amp; testing results in the lab. They&#39;re building a new molecule based off the old molecule, which takes time  
 
Just another example of Mazzy the FUDster&#39;s fraudulent posts

Ray Worthy

 it's not a copy & paste, these are my thoughts of their goals in each listed priority  
 
I'm beginning to ? your comprehension or maybe your hatred of all things Cytodyn has diminished your ability to read.  
 
Here r the answers to ur dumb ?s: 
 
i. You "continue the pending" by continuing to add additional sites & get the 1st shots into suffering patients arms. The trial is pending & continuing the work will turn pending into active duhhh 
 
ii. Pre-clinical objectives are what leads to smart clinical objectives. You'd rather they skip the groundwork so than you can go back & say they should've down pre-clinical work 1st. They're doing it the right way for future success 
 
iii. The molecules exist & they have to chose which one is best which takes lots of time modifying & testing results in the lab. They're building a new molecule based off the old molecule, which takes time  
 
Just another example of Mazzy the FUDster's fraudulent posts